TMZ-MR Is Not Actually "Banned" in Clinical Medicine—It's Prohibited in Competitive Sports
Trimetazidine modified-release (TMZ-MR) is not banned for medical use; rather, it was added to the World Anti-Doping Agency (WADA) Prohibited List on January 1,2014, as a specified stimulant prohibited during competition 1. This is a critical distinction—the drug remains approved and available for legitimate cardiovascular treatment in numerous countries worldwide.
Why WADA Prohibits Trimetazidine in Sports
The sports ban stems from trimetazidine's metabolic effects that could theoretically enhance athletic performance, particularly in endurance sports 1:
- Metabolic advantage: TMZ shifts myocardial energy substrate from fatty acid oxidation to more oxygen-efficient glucose metabolism, potentially improving physical efficiency under stress conditions
- Classification: Listed as S6b Specified Stimulant, prohibited in competition only
- Athletes affected: Evidence shows use among cyclists, athletes, and triathletes 1
Testing Complications
A notable challenge in doping control is that trimetazidine can appear in urine after administration of the permitted drug lomerizine, which undergoes metabolic conversion 2. This requires careful investigation:
- Laboratories must analyze for intact lomerizine and specific metabolites to differentiate legitimate lomerizine use from trimetazidine abuse
- In dried blood spot analysis, intact lomerizine shows strong peak intensity compared to trimetazidine 3
Clinical Use Remains Appropriate and Evidence-Based
For cardiovascular patients, trimetazidine remains a legitimate second-line antianginal agent with established benefits 4:
Approved Indications
- Symptomatic treatment of stable coronary artery disease and angina pectoris 5
- Add-on therapy for patients inadequately controlled on first-line agents (β-blockers, calcium-channel blockers) 4
Clinical Benefits
- Reduces anginal episodes and nitrate consumption
- Improves exercise tolerance
- Generally well-tolerated with mild gastrointestinal side effects 4
- Emerging evidence for heart failure with reduced ejection fraction (HFrEF): reduces cardiovascular mortality (OR 0.33) and HF hospitalizations (OR 0.42) 6
Important Contraindications
Trimetazidine is not recommended in 4:
- Parkinson disease, parkinsonism, or related movement disorders
- Severe renal impairment (creatinine clearance <30 ml/min)
Bottom Line
The "ban" is a sports doping regulation, not a clinical prohibition. Physicians should continue prescribing trimetazidine when clinically indicated for angina or potentially for HFrEF as add-on therapy 5, 7. The drug's metabolic mechanism—while potentially performance-enhancing in athletes—provides legitimate therapeutic benefit for cardiovascular patients through improved myocardial energy efficiency during ischemia 4.